Aprepitant (Emend®), profylaxe misselijkheid en braken


1. Productinformatie (Emend®) via: www.emea.eu.int/humandocs/Humans/EPAR/emend/emend/htm.
2. Hesketh PJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin -the aprepitant protocol 052 study group. J Clin Oncol 2003; 21: 4112-4119. 
3. Poli-Bigelli S, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
4. CFH-rapporten aprepitant (Emend®) via: www.cvz.nl, CFH-rapporten.
5. EPAR Emend (aprepitant). CPMP/4521/03. EMEA 2003.  

Auteurs

  • dr D. Bijl